Compare UA & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UA | MESO |
|---|---|---|
| Founded | 1996 | 2004 |
| Country | United States | Australia |
| Employees | 14400 | 81 |
| Industry | Apparel | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 2.2B |
| IPO Year | N/A | N/A |
| Metric | UA | MESO |
|---|---|---|
| Price | $5.95 | $14.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.5M | 250.8K |
| Earning Date | 02-06-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $644.56 |
| Revenue Next Year | $1.72 | $38.70 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.95 | $9.61 |
| 52 Week High | $7.91 | $21.50 |
| Indicator | UA | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 36.67 | 39.40 |
| Support Level | $5.88 | $14.74 |
| Resistance Level | $6.44 | $16.33 |
| Average True Range (ATR) | 0.27 | 0.50 |
| MACD | -0.13 | -0.02 |
| Stochastic Oscillator | 11.87 | 45.65 |
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America, Asia-Pacific, Europe, and Latin America. Consumers of its performance-based clothing and shoes include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through wholesale partners, company-owned digital channels, and approximately 450 company-owned outlet and full-price stores. The Baltimore-based firm was founded in 1996 and is led by controlling shareholder Kevin Plank.
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.